These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 28574977)
1. Development of a biclonal cutaneous T-cell lymphoproliferative process during treatment with immune checkpoint inhibitors for metastatic melanoma. Davick JJ; Wick MR; Gru AA Melanoma Res; 2017 Aug; 27(4):383-386. PubMed ID: 28574977 [TBL] [Abstract][Full Text] [Related]
3. The role of nivolumab in melanoma. Gomes F; Serra-Bellver P; Lorigan P Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782 [TBL] [Abstract][Full Text] [Related]
5. Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma. Maurice C; Schneider R; Kiehl TR; Bavi P; Roehrl MH; Mason WP; Hogg D Cancer Immunol Res; 2015 Dec; 3(12):1299-302. PubMed ID: 26419960 [TBL] [Abstract][Full Text] [Related]
6. Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma. Reddy SB; Possick JD; Kluger HM; Galan A; Han D J Immunother; 2017 Oct; 40(8):307-311. PubMed ID: 28737620 [TBL] [Abstract][Full Text] [Related]
7. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165 [TBL] [Abstract][Full Text] [Related]
8. Development of Bell's Palsy After Treatment With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report. Zecchini JM; Kim S; Yum K; Friedlander P J Immunother; 2018 Jan; 41(1):39-41. PubMed ID: 28926356 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884 [TBL] [Abstract][Full Text] [Related]
10. Primary Cutaneous Small/Medium CD4+ T-CELL Lymphoproliferative Disorder Occurring in a Patient With Metastatic Melanoma. Davick JJ; Gaughan E; Barry M; Gru AA Am J Dermatopathol; 2018 Jan; 40(1):60-63. PubMed ID: 28719434 [TBL] [Abstract][Full Text] [Related]
11. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415 [TBL] [Abstract][Full Text] [Related]
12. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. Camacho LH Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164 [TBL] [Abstract][Full Text] [Related]
13. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Morganstein DL; Lai Z; Spain L; Diem S; Levine D; Mace C; Gore M; Larkin J Clin Endocrinol (Oxf); 2017 Apr; 86(4):614-620. PubMed ID: 28028828 [TBL] [Abstract][Full Text] [Related]
14. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. Firwana B; Ravilla R; Raval M; Hutchins L; Mahmoud F J Oncol Pharm Pract; 2017 Dec; 23(8):620-624. PubMed ID: 27590328 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic use of anti-CTLA-4 antibodies. Blank CU; Enk A Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057 [TBL] [Abstract][Full Text] [Related]
16. Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern. Trinidad C; Nelson KC; Glitza Oliva IC; Torres-Cabala CA; Nagarajan P; Tetzlaff MT; Ivan D; Hwu WJ; Prieto VG; Curry JL; Aung PP J Cutan Pathol; 2018 Jul; 45(7):504-507. PubMed ID: 29633300 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in melanoma: Recent advances and future directions. Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635 [TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482 [TBL] [Abstract][Full Text] [Related]
20. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Ott PA; Hodi FS; Robert C Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]